Loading clinical trials...

COMPLETEDNA

Glucose Meter Study

A New Contour Blood Glucose Monitoring System With High Frequency Testing Patients

NCT00782496•Ascensia Diabetes Care

Summary

The purpose of this study is to evaluate if the meal marker and reminder feature of the Contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that may lead to improvement in glycemic control.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Persons with type 1 or type 2 diabetes
•2. Persons who are on a pump or are taking at least 1 mealtime injection of insulin a day
•3. Persons at least 21 years of age
•4. Persons willing to complete all study visits and study procedures including:
•* Using the meal-marker + reminder feature regularly (Group 2 subjects only)
•* Using the paper logbook provided (both Groups)
•5. Testing their BG at least 3 times a day during the entire study.
•6. Persons who are able to speak, read and understand English
•7. Persons who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more

Exclusion Criteria

•1. Persons who have been using a CONTOUR, BREEZE or BREEZE 2 meter regularly during the previous 6 months
•2. Persons who test over 6 times/day regularly
•3. Persons who wear a BG sensor 2 weeks or more during each month.
•4. Persons with home heath aides who assist with their BG testing.
•5. Persons with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:
•* Significant visual impairment
•* Significant hearing impairment
•* Cognitive disorder
•* Significant unstable co-morbidity (with notable change within the past 3 months)
•6. Any other condition as per investigator's discretion

Locations (4)

Atlanta Diabetes Associates

Atlanta, Georgia, United States

International Diabetes Center

Minneapolis, Minnesota, United States

Mount Sinai School of Medicine

New York, New York, United States

University of Washington Medical Center/Diabetes Care Center

Seattle, Washington, United States

Key Dates

Start Date

November 1, 2008

Primary Completion Date

September 1, 2009

Completion Date

September 1, 2009

Last Updated

February 29, 2016

Enrollment

211

ACTUAL participants

Conditions

Diabetes Mellitus

Interventions

Education + new meter

DEVICE

Education + new meter + feature activation

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 29, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Glucose Meter Study

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Achieving Routine Intervention and Screening for Emotional Health